How many weeks' holiday a year are there?
picture of 50 mg tramadol In the spring BTG agreed to pay $180 million in cash and up to $40 million in milestones for Seattle-area company Ekos, which gave it control of EkoSonic, a new technology approved in the U.S. and Europe for treating blood clots. The biotech has been developing the product for use in hospitals--making it a good match for Varithena. Earlier BTG nabbed the targeted therapies division of Nordion for $200 million, getting its hands on Therasphere, which uses radioactive glass beads in a targeted approach to treating liver cancer.